Spectral Diagnostics provides update on results of annual and special meeting of shareholders

About this update from Spectral Medical Inc

[{"type":"text","content":"\n\n\nTORONTO, May 6, 2014 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the \"Corporation\") today announced that at the annual and special meeting (the \"Meeting\") of shareholders of the Corporation (\"Shareholders\") that was held yesterday, all six nominees for the board were elected,\n the voting results of which are as follows:\n\n\n\n\nDirector\n\n\nNumber and percentage of \nshares represented in person or \nby proxy and entitled to vote at \nthe Meeting that voted FOR\n\n\nNumber and percentage of \nshares represented in person or \nby proxy and entitled to vote at \nthe Meeting that were \nWITHHELD from voting\n\n\n\n\nAnthony Bihl III\n\n\n74,241,553 (99.55%)\n\n\n339,181 (0.45%)\n\n\n\n\nKevin Giese\n\n\n71,632,600 (96.05%)\n\n\n2,948,134 (3.95%)\n\n\n\n\nGuillermo Herrera\n\n\n74,084,173 (99.33%)\n\n\n496,561 (0.67%)\n\n\n\n\nPaul M. Walker\n\n\n74,141,164 (99.41%)\n\n\n439,570 (0.59%)\n\n\n\n\nLaine Woollard\n\n\n74,094,776 (99.35%)\n\n\n485,958 (0.65%)\n\n\n\n\nKoichiro Takeshita\n\n\n74,254,387 (99.56%)\n\n\n326,347 (0.44%)\n\n\n\n\n\n\n\nAt the Meeting, Shareholder also approved the name change of the\n Corporation to \"Spectral Medical Inc.\" but that name change will only\n take effect if, as and when adopted by the board of directors of the\n Corporation at a later date.  Lastly, Shareholders also approved the\n amendments to the terms of those certain warrants of the Corporation\n held by insiders to extend the expiry date of the warrants from March\n 2, 2014 to September 2, 2014, consistent with the amendments made to\n the warrants held by all other holders of warrants.\n\n\nFull details of the foregoing are contained in the Report of Voting\n Results for the Meeting which has been filed on Sedar at www.Sedar.com.\n\n\nAbout Spectral Diagnostics\n\n\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment of severe sepsis with septic\n shock. PMX is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. Directed by\n the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared\n diagnostic for the risk of developing sepsis. Spectral's EUPHRATES\n trial is the world's only active and most innovative Phase III study in\n the area of septic shock.\n\n\nPMX has been ap...

More updates from Spectral Medical Inc